A scoring system to predict renal outcome in IgA nephropathy: a nationwide 10-year prospective cohort study
暂无分享,去创建一个
Masahiko Ando | Takashi Kawamura | Masashi Goto | Kenji Wakai | Yasuhiko Tomino | M. Ando | M. Goto | T. Kawamura | K. Wakai | M. Endoh | Y. Tomino | Masayuki Endoh
[1] O. Kardaun,et al. Toward individual prognosis of IgA nephropathy. , 1986, Kidney international.
[2] B. Julian,et al. Angiotensin converting enzyme gene polymorphism: potential silencer motif and impact on progression in IgA nephropathy. , 1996, Kidney international.
[3] S. Lemeshow,et al. Mortality Probability Models (MPM II) based on an international cohort of intensive care unit patients. , 1993, JAMA.
[4] Y. Yamaji,et al. Angiotensin-converting-enzyme inhibitors slow renal decline in IgA nephropathy, independent of tubulointerstitial fibrosis at presentation. , 2005, QJM : monthly journal of the Association of Physicians.
[5] D. Cattran,et al. Long-term benefits of angiotensin-converting enzyme inhibitor therapy in patients with severe immunoglobulin a nephropathy: a comparison to patients receiving treatment with other antihypertensive agents and to patients receiving no therapy. , 1994, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[6] F. Guillemin,et al. Polymorphism of angiotensin converting enzyme, angiotensinogen, and angiotensin II type 1 receptor genes and end-stage renal failure in IgA nephropathy: IGARAS--a study of 274 Men. , 2000, Journal of the American Society of Nephrology : JASN.
[7] M. Lam,et al. A family-based association study of megsin A23167G polymorphism with susceptibility and progression of IgA nephropathy in a Chinese population. , 2006, Clinical nephrology.
[8] A. Tamakoshi,et al. Significance of urinalysis for subsequent kidney and urinary tract disorders in mass screening of adults. , 1995, Internal medicine.
[9] J. Connell,et al. Polymorphisms in angiotensin-converting-enzyme gene and progression of IgA nephropathy , 1995, The Lancet.
[10] Zhi-Hong Liu,et al. Epidemiologic data of renal diseases from a single unit in China: analysis based on 13,519 renal biopsies. , 2004, Kidney international.
[11] K. Thai,et al. Association of angiotensinogen gene T235 variant with progression of immunoglobin A nephropathy in Caucasian patients. , 1997, The Journal of clinical investigation.
[12] C. Ponticelli,et al. Long-term follow-up of IgA mesangial nephropathy: clinico-histological study in 374 patients. , 1987, Seminars in nephrology.
[13] Yasuhiko Tomino,et al. Revised equations for estimated GFR from serum creatinine in Japan. , 2009, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[14] F. Schena,et al. Increased risk of end-stage renal disease in familial IgA nephropathy. , 2002, Journal of the American Society of Nephrology : JASN.
[15] L. Gesualdo,et al. ACE gene polymorphism and IgA nephropathy: an ethnically homogeneous study and a meta-analysis. , 2001, Kidney international.
[16] K. Chow,et al. Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[17] J. Berger,et al. [Intercapillary deposits of IgA-IgG]. , 1968, Journal d'urologie et de nephrologie.
[18] R. Nieuwland,et al. Plasma markers of coagulation and endothelial activation in Fabry disease: impact of renal impairment. , 2009, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[19] É. Renoult,et al. IgA nephropathy: prognostic classification of end-stage renal failure. L'Association des Néphrologues de l'Est. , 1997 .
[20] G. D'Amico,et al. Natural history of idiopathic IgA nephropathy: role of clinical and histological prognostic factors. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[21] M. Arakawa,et al. Clinical guidelines of IgA nephropathy. , 1995, Nihon Jinzo Gakkai shi.
[22] Y. Taguma,et al. Tonsillectomy and steroid pulse therapy significantly impact on clinical remission in patients with IgA nephropathy. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[23] I. Narita,et al. The efficacy of tonsillectomy on long-term renal survival in patients with IgA nephropathy. , 2003, Kidney international.
[24] A. Tamakoshi,et al. A scoring system to predict renal outcome in IgA nephropathy: from a nationwide prospective study. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[25] F. Berthoux,et al. Prognostic factors in mesangial IgA glomerulonephritis: an extensive study with univariate and multivariate analyses. , 1991, American Journal of Kidney Diseases.
[26] J Crowley,et al. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. , 1999, Statistics in medicine.
[27] E. Morales,et al. Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial. , 2003, Journal of the American Society of Nephrology : JASN.
[28] P. Zucchelli,et al. [IgA nephropathy]. , 1985, Medicina clinica.
[29] J. Craig,et al. Immunosuppressive agents for treating IgA nephropathy. , 2003, The Cochrane database of systematic reviews.
[30] C. Charasse,et al. Epidemiologic data of primary glomerular diseases in western France. , 2004, Kidney international.
[31] G. Maschio,et al. ACE inhibition reduces proteinuria in normotensive patients with IgA nephropathy: a multicentre, randomized, placebo-controlled study. , 1994, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[32] F. Scolari,et al. IgA nephropathy: the presence of familial disease does not confer an increased risk for progression. , 2006, American journal of kidney diseases : the official journal of the National Kidney Foundation.